Fig. 5

Gene expression levels of MMP11 as a potential predictor of PCa patients’ outcome. A MMP11 and (B) MMP26 mRNA expression levels were correlated with Gleason score in several independent datasets (PRAD TCGA, n = 498; DKFZ, n = 118; and MSKCC primary and metastatic, n = 150). Q: quartile. C The Kaplan–Meier analyses of the association of MMP11 expression and clinical outcomes in the PCa gene expression datasets TCGA PRAD (n = 407), MSKCC (n = 140), DKFZ (n = 105), and SU2C/PCF Dream Team (n = 81). The patients were stratified by the most significant cut-off for MMP11 expression levels. D The Kaplan–Meier analyses of the association of MMP26 expression and BRFS in the TCGA PRAD gene expression dataset (n = 407). The patients were stratified by the most significant cut-off for MMP26 expression levels. E A combined MMP11 high/MMP26 low gene expression signature improves the prediction of BRFS in the TCGA PRAD gene expression dataset (n = 407). (F) A relative expression of MMP11 and MMP26 genes in non-cancerous tissues, primary and metastatic tumors (MSKCC dataset). Statistics was performed by one-way ANOVA followed by posthoc Tukey HSD test. The error bars denote the 5th and 95th percentile values. *p < 0.05; **p < 0.01